Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system

The Intelligent Dosing System (IDS, Dimensional Dosing Systems, Inc., Wexford, PA) is a software suite that incorporates patient-specific, dose-response data in a mathematical model, and then calculates the new dose of agent needed to achieve the next desired therapeutic goal. We evaluated use of th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes technology & therapeutics 2004-06, Vol.6 (3), p.326-335
Hauptverfasser: Cook, Curtiss B, Mann, Linda J, King, Esther C, New, Katina M, Vaughn, Pamela S, Dames, Faye D, Dunbar, Virginia G, Caudle, Jane M, Tsui, Circe, George, Christopher D, McMichael, John P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 335
container_issue 3
container_start_page 326
container_title Diabetes technology & therapeutics
container_volume 6
creator Cook, Curtiss B
Mann, Linda J
King, Esther C
New, Katina M
Vaughn, Pamela S
Dames, Faye D
Dunbar, Virginia G
Caudle, Jane M
Tsui, Circe
George, Christopher D
McMichael, John P
description The Intelligent Dosing System (IDS, Dimensional Dosing Systems, Inc., Wexford, PA) is a software suite that incorporates patient-specific, dose-response data in a mathematical model, and then calculates the new dose of agent needed to achieve the next desired therapeutic goal. We evaluated use of the IDS for titrating insulin therapy. The IDS was placed on handheld platforms and provided to practitioners to use in adjusting total daily insulin dose. Fasting glucose, random glucose, and hemoglobin A1c were used as markers against which insulin could be adjusted. Values of markers expected at the next follow-up visit, as predicted by the model, were compared with levels actually observed. For 264 patients, 334 paired visits were analyzed. Average age was 54 years, diabetes' duration was 10 years, and body mass index was 33.2 kg/m(2); 57% were female, 88% were African American, and 92% had type 2 diabetes. The correlation between IDS suggested and actual prescribed total daily dose was high (r = 0.99), suggesting good acceptability of the IDS by practitioners. Significant decreases in fasting glucose, random glucose, and hemoglobin A1c levels were seen (all P < 0.0001). No significant difference between average expected and observed follow-up fasting glucose values was found (145 vs. 149 mg/dL, P = 0.42), and correlation was high (r = 0.79). Mean observed random glucose value at follow-up was comparable to the IDS predicted level (167 vs. 168 mg/dL, P = 0.97), and correlation was high (r = 0.73). Observed follow-up hemoglobin A1c was higher than the value expected (7.9% vs. 7.4%, P < 0.0055), but correlation was good (r = 0.70). These analyses suggest the IDS is a useful adjunct for decisions regarding insulin therapy even when using a variety of markers of glucose control, and can be used by practitioners to assist in attainment of glycemic goals.
doi_str_mv 10.1089/152091504774198016
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72026308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72026308</sourcerecordid><originalsourceid>FETCH-LOGICAL-c214t-8a093f2a5128ba1ea01b33e752f04f6eb85cd0a8538b76eb0360a174b3ccfb2f3</originalsourceid><addsrcrecordid>eNplkE1LxDAQhoMofv8BD5KTt-okadr0KOIXKF70XCbtZI206dqkh_33ZnHBg6eZged9GF7GLgRcCzDNjdASGqGhrOtSNAZEtceOhdZ1YXSj9re7hCIT1RE7ifELAGolxSE7EjrzRuljFl4x4IpGColPjvsQl8EHnj5pxvUm33yZLQbee7SUKPI1Jp_hyH3kDjs_-ISJem43fIm0dWTah0TD4Fdbaz9FH1Y8bmKi8YwdOBwine_mKft4uH-_eype3h6f725fik6KMhUGoVFOohbSWBSEIKxSVGvpoHQVWaO7HtBoZWydT1AVoKhLq7rOWenUKbv69a7n6XuhmNrRxy7_hIGmJba1BFkpMBmUv2A3TzHO5Nr17EecN62Adtty-7_lHLrc2Rc7Uv8X2dWqfgAyzXkj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72026308</pqid></control><display><type>article</type><title>Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system</title><source>Mary Ann Liebert Online Subscription</source><source>MEDLINE</source><creator>Cook, Curtiss B ; Mann, Linda J ; King, Esther C ; New, Katina M ; Vaughn, Pamela S ; Dames, Faye D ; Dunbar, Virginia G ; Caudle, Jane M ; Tsui, Circe ; George, Christopher D ; McMichael, John P</creator><creatorcontrib>Cook, Curtiss B ; Mann, Linda J ; King, Esther C ; New, Katina M ; Vaughn, Pamela S ; Dames, Faye D ; Dunbar, Virginia G ; Caudle, Jane M ; Tsui, Circe ; George, Christopher D ; McMichael, John P</creatorcontrib><description>The Intelligent Dosing System (IDS, Dimensional Dosing Systems, Inc., Wexford, PA) is a software suite that incorporates patient-specific, dose-response data in a mathematical model, and then calculates the new dose of agent needed to achieve the next desired therapeutic goal. We evaluated use of the IDS for titrating insulin therapy. The IDS was placed on handheld platforms and provided to practitioners to use in adjusting total daily insulin dose. Fasting glucose, random glucose, and hemoglobin A1c were used as markers against which insulin could be adjusted. Values of markers expected at the next follow-up visit, as predicted by the model, were compared with levels actually observed. For 264 patients, 334 paired visits were analyzed. Average age was 54 years, diabetes' duration was 10 years, and body mass index was 33.2 kg/m(2); 57% were female, 88% were African American, and 92% had type 2 diabetes. The correlation between IDS suggested and actual prescribed total daily dose was high (r = 0.99), suggesting good acceptability of the IDS by practitioners. Significant decreases in fasting glucose, random glucose, and hemoglobin A1c levels were seen (all P &lt; 0.0001). No significant difference between average expected and observed follow-up fasting glucose values was found (145 vs. 149 mg/dL, P = 0.42), and correlation was high (r = 0.79). Mean observed random glucose value at follow-up was comparable to the IDS predicted level (167 vs. 168 mg/dL, P = 0.97), and correlation was high (r = 0.73). Observed follow-up hemoglobin A1c was higher than the value expected (7.9% vs. 7.4%, P &lt; 0.0055), but correlation was good (r = 0.70). These analyses suggest the IDS is a useful adjunct for decisions regarding insulin therapy even when using a variety of markers of glucose control, and can be used by practitioners to assist in attainment of glycemic goals.</description><identifier>ISSN: 1520-9156</identifier><identifier>EISSN: 1557-8593</identifier><identifier>DOI: 10.1089/152091504774198016</identifier><identifier>PMID: 15198835</identifier><language>eng</language><publisher>United States</publisher><subject>Artificial Intelligence ; Blood Glucose - analysis ; Diabetes Mellitus, Type 1 - drug therapy ; Equipment Design ; Humans ; Insulin - administration &amp; dosage ; Insulin - therapeutic use ; Insulin Infusion Systems ; Monitoring, Ambulatory - methods ; United States ; United States Food and Drug Administration</subject><ispartof>Diabetes technology &amp; therapeutics, 2004-06, Vol.6 (3), p.326-335</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c214t-8a093f2a5128ba1ea01b33e752f04f6eb85cd0a8538b76eb0360a174b3ccfb2f3</citedby><cites>FETCH-LOGICAL-c214t-8a093f2a5128ba1ea01b33e752f04f6eb85cd0a8538b76eb0360a174b3ccfb2f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3042,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15198835$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cook, Curtiss B</creatorcontrib><creatorcontrib>Mann, Linda J</creatorcontrib><creatorcontrib>King, Esther C</creatorcontrib><creatorcontrib>New, Katina M</creatorcontrib><creatorcontrib>Vaughn, Pamela S</creatorcontrib><creatorcontrib>Dames, Faye D</creatorcontrib><creatorcontrib>Dunbar, Virginia G</creatorcontrib><creatorcontrib>Caudle, Jane M</creatorcontrib><creatorcontrib>Tsui, Circe</creatorcontrib><creatorcontrib>George, Christopher D</creatorcontrib><creatorcontrib>McMichael, John P</creatorcontrib><title>Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system</title><title>Diabetes technology &amp; therapeutics</title><addtitle>Diabetes Technol Ther</addtitle><description>The Intelligent Dosing System (IDS, Dimensional Dosing Systems, Inc., Wexford, PA) is a software suite that incorporates patient-specific, dose-response data in a mathematical model, and then calculates the new dose of agent needed to achieve the next desired therapeutic goal. We evaluated use of the IDS for titrating insulin therapy. The IDS was placed on handheld platforms and provided to practitioners to use in adjusting total daily insulin dose. Fasting glucose, random glucose, and hemoglobin A1c were used as markers against which insulin could be adjusted. Values of markers expected at the next follow-up visit, as predicted by the model, were compared with levels actually observed. For 264 patients, 334 paired visits were analyzed. Average age was 54 years, diabetes' duration was 10 years, and body mass index was 33.2 kg/m(2); 57% were female, 88% were African American, and 92% had type 2 diabetes. The correlation between IDS suggested and actual prescribed total daily dose was high (r = 0.99), suggesting good acceptability of the IDS by practitioners. Significant decreases in fasting glucose, random glucose, and hemoglobin A1c levels were seen (all P &lt; 0.0001). No significant difference between average expected and observed follow-up fasting glucose values was found (145 vs. 149 mg/dL, P = 0.42), and correlation was high (r = 0.79). Mean observed random glucose value at follow-up was comparable to the IDS predicted level (167 vs. 168 mg/dL, P = 0.97), and correlation was high (r = 0.73). Observed follow-up hemoglobin A1c was higher than the value expected (7.9% vs. 7.4%, P &lt; 0.0055), but correlation was good (r = 0.70). These analyses suggest the IDS is a useful adjunct for decisions regarding insulin therapy even when using a variety of markers of glucose control, and can be used by practitioners to assist in attainment of glycemic goals.</description><subject>Artificial Intelligence</subject><subject>Blood Glucose - analysis</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Equipment Design</subject><subject>Humans</subject><subject>Insulin - administration &amp; dosage</subject><subject>Insulin - therapeutic use</subject><subject>Insulin Infusion Systems</subject><subject>Monitoring, Ambulatory - methods</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>1520-9156</issn><issn>1557-8593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkE1LxDAQhoMofv8BD5KTt-okadr0KOIXKF70XCbtZI206dqkh_33ZnHBg6eZged9GF7GLgRcCzDNjdASGqGhrOtSNAZEtceOhdZ1YXSj9re7hCIT1RE7ifELAGolxSE7EjrzRuljFl4x4IpGColPjvsQl8EHnj5pxvUm33yZLQbee7SUKPI1Jp_hyH3kDjs_-ISJem43fIm0dWTah0TD4Fdbaz9FH1Y8bmKi8YwdOBwine_mKft4uH-_eype3h6f725fik6KMhUGoVFOohbSWBSEIKxSVGvpoHQVWaO7HtBoZWydT1AVoKhLq7rOWenUKbv69a7n6XuhmNrRxy7_hIGmJba1BFkpMBmUv2A3TzHO5Nr17EecN62Adtty-7_lHLrc2Rc7Uv8X2dWqfgAyzXkj</recordid><startdate>200406</startdate><enddate>200406</enddate><creator>Cook, Curtiss B</creator><creator>Mann, Linda J</creator><creator>King, Esther C</creator><creator>New, Katina M</creator><creator>Vaughn, Pamela S</creator><creator>Dames, Faye D</creator><creator>Dunbar, Virginia G</creator><creator>Caudle, Jane M</creator><creator>Tsui, Circe</creator><creator>George, Christopher D</creator><creator>McMichael, John P</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200406</creationdate><title>Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system</title><author>Cook, Curtiss B ; Mann, Linda J ; King, Esther C ; New, Katina M ; Vaughn, Pamela S ; Dames, Faye D ; Dunbar, Virginia G ; Caudle, Jane M ; Tsui, Circe ; George, Christopher D ; McMichael, John P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c214t-8a093f2a5128ba1ea01b33e752f04f6eb85cd0a8538b76eb0360a174b3ccfb2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Artificial Intelligence</topic><topic>Blood Glucose - analysis</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Equipment Design</topic><topic>Humans</topic><topic>Insulin - administration &amp; dosage</topic><topic>Insulin - therapeutic use</topic><topic>Insulin Infusion Systems</topic><topic>Monitoring, Ambulatory - methods</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cook, Curtiss B</creatorcontrib><creatorcontrib>Mann, Linda J</creatorcontrib><creatorcontrib>King, Esther C</creatorcontrib><creatorcontrib>New, Katina M</creatorcontrib><creatorcontrib>Vaughn, Pamela S</creatorcontrib><creatorcontrib>Dames, Faye D</creatorcontrib><creatorcontrib>Dunbar, Virginia G</creatorcontrib><creatorcontrib>Caudle, Jane M</creatorcontrib><creatorcontrib>Tsui, Circe</creatorcontrib><creatorcontrib>George, Christopher D</creatorcontrib><creatorcontrib>McMichael, John P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes technology &amp; therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cook, Curtiss B</au><au>Mann, Linda J</au><au>King, Esther C</au><au>New, Katina M</au><au>Vaughn, Pamela S</au><au>Dames, Faye D</au><au>Dunbar, Virginia G</au><au>Caudle, Jane M</au><au>Tsui, Circe</au><au>George, Christopher D</au><au>McMichael, John P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system</atitle><jtitle>Diabetes technology &amp; therapeutics</jtitle><addtitle>Diabetes Technol Ther</addtitle><date>2004-06</date><risdate>2004</risdate><volume>6</volume><issue>3</issue><spage>326</spage><epage>335</epage><pages>326-335</pages><issn>1520-9156</issn><eissn>1557-8593</eissn><abstract>The Intelligent Dosing System (IDS, Dimensional Dosing Systems, Inc., Wexford, PA) is a software suite that incorporates patient-specific, dose-response data in a mathematical model, and then calculates the new dose of agent needed to achieve the next desired therapeutic goal. We evaluated use of the IDS for titrating insulin therapy. The IDS was placed on handheld platforms and provided to practitioners to use in adjusting total daily insulin dose. Fasting glucose, random glucose, and hemoglobin A1c were used as markers against which insulin could be adjusted. Values of markers expected at the next follow-up visit, as predicted by the model, were compared with levels actually observed. For 264 patients, 334 paired visits were analyzed. Average age was 54 years, diabetes' duration was 10 years, and body mass index was 33.2 kg/m(2); 57% were female, 88% were African American, and 92% had type 2 diabetes. The correlation between IDS suggested and actual prescribed total daily dose was high (r = 0.99), suggesting good acceptability of the IDS by practitioners. Significant decreases in fasting glucose, random glucose, and hemoglobin A1c levels were seen (all P &lt; 0.0001). No significant difference between average expected and observed follow-up fasting glucose values was found (145 vs. 149 mg/dL, P = 0.42), and correlation was high (r = 0.79). Mean observed random glucose value at follow-up was comparable to the IDS predicted level (167 vs. 168 mg/dL, P = 0.97), and correlation was high (r = 0.73). Observed follow-up hemoglobin A1c was higher than the value expected (7.9% vs. 7.4%, P &lt; 0.0055), but correlation was good (r = 0.70). These analyses suggest the IDS is a useful adjunct for decisions regarding insulin therapy even when using a variety of markers of glucose control, and can be used by practitioners to assist in attainment of glycemic goals.</abstract><cop>United States</cop><pmid>15198835</pmid><doi>10.1089/152091504774198016</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1520-9156
ispartof Diabetes technology & therapeutics, 2004-06, Vol.6 (3), p.326-335
issn 1520-9156
1557-8593
language eng
recordid cdi_proquest_miscellaneous_72026308
source Mary Ann Liebert Online Subscription; MEDLINE
subjects Artificial Intelligence
Blood Glucose - analysis
Diabetes Mellitus, Type 1 - drug therapy
Equipment Design
Humans
Insulin - administration & dosage
Insulin - therapeutic use
Insulin Infusion Systems
Monitoring, Ambulatory - methods
United States
United States Food and Drug Administration
title Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T07%3A57%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20insulin%20therapy%20in%20urban%20diabetes%20patients%20is%20facilitated%20by%20use%20of%20an%20intelligent%20dosing%20system&rft.jtitle=Diabetes%20technology%20&%20therapeutics&rft.au=Cook,%20Curtiss%20B&rft.date=2004-06&rft.volume=6&rft.issue=3&rft.spage=326&rft.epage=335&rft.pages=326-335&rft.issn=1520-9156&rft.eissn=1557-8593&rft_id=info:doi/10.1089/152091504774198016&rft_dat=%3Cproquest_cross%3E72026308%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72026308&rft_id=info:pmid/15198835&rfr_iscdi=true